Central role of the AT1-receptor in atherosclerosis

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S26-S33

  Nickenig, G ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

At1 receptors; Atherosclerosis; Oxidised LDL; Reactive oxygen species; Renin angiotensin system; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CD11B ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RENIN; SODIUM CHLORIDE; SUPEROXIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; WATER;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CELL FUNCTION; CELL HYPERPLASIA; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; DRUG SPECIFICITY; ENDOTHELIUM LESION; ESTROGEN DEFICIENCY; EVIDENCE BASED MEDICINE; FLUID BALANCE; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTROPHY; INHIBITION KINETICS; KIDNEY FUNCTION; METABOLIC REGULATION; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTECTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM BALANCE; TREATMENT PLANNING; VASCULAR LESION; VASOCONSTRICTION;

ARTERIOSCLEROSIS; BRAIN; HUMANS; HYPERCHOLESTEROLEMIA; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN;

EID: 0036672582     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001436     Document Type: Article

References (96)

1. Peach MJ. Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev 1977; 57: 313-370.
2. Griendling KK, Murphy TJ, Alexander RW. Molecular biologv of the renin-angiotensin system. Circulation1993; 87: 1816-1828.
3. Timmermans PB Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993; 45: 205-251.
4. Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996; 36: 281-306.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl Med 1999; 340: 115-126.
6. Vaughan DE. AT, receptor blockade and atherosclerosis, hopeful insights into vascular protection. Circulation 2000; 101: 1496-1497.
7. Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. JRAAS2000; 1: 11-17.
8. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme.Hypertens 1999; 17: 1775- 1786.
9. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-163.
10. Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br f Pharmacol 2000; 130: 947-962.
11. Lemay J, Hamet P, de Blois D. Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. JRAAS 2000; 1: 46-50.
12. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart 1998; 19 (Suppl 1): J2-J6.
13. Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-949.
14. Babior BM. Phagocytes and oxidative stress. Am J Med2000; 109: 33-44.
15. Hensley K Reactive oxygen species, cell signaling, and cell injury. Free Radie Biol Med 2000; 28: 1456-1462.
16. Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. Circ Res 1999; 85: 562-563.
17. Harrison DG. Endothelial function and oxidatant stress. Clin Cardiol 1997; 20 (Suppl): 11-11-11-17.
18. Patel RP Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radie Biol Med2000; 28:1780-1794.
19. Pueyo ME Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor- kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vase Biol 2000; 20: 645- 651.
20. Usui M Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.
21. Luft FC Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999; 33: 212-218.
22. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am Physiol (Cell Physiol) 2001; 280: C53-C60.
23. Janiszewski M Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Cardiovasc Res 1998; 39: 327-338.
24. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997; 432: 35-44.
25. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res 1994; 74:1141-1148.
26. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biologv and disease. Circ Res 2000; 86: 494-501.
27. Suh YA et al. Cell transformation by the superoxide- generating oxidase Moxl. Nature 1999; 401: 79-82.
28. Meyer JW, Schmitt ME. A central role for the endothelial NAD(P)H oxidase in atherosclerosis. FEBS Lett2000; 472: 1-4.
29. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vase Biol 2000; 20: 2175-2183.
30. Wassmann S Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin ATl-receptor expression and racl GTPase. Mol Pharmacol 2001; 59: 646-654.
31. Wang W Superoxide production and reactive oxygen species signaling by endothelial nitric-oxide synthase.Biol Chem 2000; 275: 16899-16903.
32. Shinozaki K Oral administration of tetrahydrobi- opterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87: 566-573.
33. Shinozaki K Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/02-imbalance in insu- lin-resistant rat aorta. Diabetes 1999; 48: 2437-2445.
34. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. Biol Chem 1998; 273: 25804- 25808.
35. Vasquez-Vivar J Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-9225.
36. Hink U Mechanisms underlying endothelial dys-function in diabetes mellitus. Cire Res 2001; 88: el4-e22.
37. Hsieh HJ Increase of reactive oxygen species in endothelial (ROS) cells by shear flow and involvement of ROS in shear-induced c-fos expression.Cell Physiol 1998; 175: 156-162.
38. Abe J, Berk BC. Fyn and JAK2 mediate RAS activation by reactive oxygen species. Biol Chem 1999; 274: 21003-21010.
39. Kawakami M, Okabe E. Superoxide anion radical-trig- gered Ca2+ release from cardiac sarcoplasmatic reticulum through ryanodine receptor Ca2+ channel. Mol Pharmacol 1998; 53: 497-503.
40. Ushio-Fukai M, Wayne Alexander R, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Biol Chem1998; 273: 15022-15029.
41. Ushio-Fukai M Reactive oxygen species mediate the activation of akt/protein kinase B by angiotensin II in vascular smooth muscle cells. Biol Chem 1999; 274: 22699-22704.
42. TOMASIAN D, KEANEY JF, VITA JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res 2000; 47: 426-435.
43. Laursen JB et al. Role of superoxide in angiotensin II- induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
44. Mancini JGB Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258-265.
45. Prasad A Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354.
46. Schiffrin EL, Park JB, Intengan HD, Touyz R. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
47. Kranzhöfer R, Browatzki M, Schmidt J, Kiibler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor - kB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-828.
48. Morawietz H Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902.
49. Keidar S, Attias J. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun 1997; 239: 63-67.
50. Schieffer B Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378.
51. Castelli WP Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-2838.
52. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am f Med 1986; 80: 23-32.
53. Gunther S, Gimbrone MA, Alexander RW. Regulation by angiotensin II of its receptors in resistance blood vessels. Nature 1980; 287: 230-232.
54. Douglas JG, Brown GP. Effect of prolonged low dose infusion of angiotensin II and aldosterone on rat smooth muscle and adrenal angiotensin II receptors. Endocrinology 1982; 111: 988-992.
55. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am Physiol 1984; 246 (Heart Circ Physiol 15): H608-H614.
56. Griendling KK Correlation of receptor sequestration with sustained diacylglycerol accumulation in angiotensin II-stimulated cultured vascular smooth muscle cells.Biol Chem 1987; 262: 14555-14562.
57. Lassegue B Angiotensin II down regulates the vascular smooth muscle ATI receptor by transcriptional and post-transcriptional mechanisms: evidence for homologuos and heterologous regulation. Mol Pharmacol 1995; 48: 601-609.
58. Nickenig G, Murphy TJ. Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression. Mol Pharmacol 1994; 46: 653-659.
59. Ichiki T Down-regulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 1998; 31: 342-348.
60. Ikeda Y Transcriptional suppression of rat angiotensin ATla receptor gene expression by interferon- gamma in vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 262: 494-498.
61. Nickenig G Insulin induces up-regulation of vascular ATI receptor gene expression by post-transcrip- tional mechanisms. Circulation 1998; 98: 2453-2460.
62. Nickenig G Salt induces vascular ATI receptor overexpression in vitro and in vivo. Hypertension1998; 31: 1272-1277.
63. Nickenig G Negative feedback regulation of reactive oxygen species on ATI receptor gene expression. Br f Pharmacol 2000; 131: 795-803.
64. Takeda K Down-regulation of angiotensin II type receptor by all-trans retinoic acid in vascular smooth muscle cells. Hypertension 2000; 35: 297-302.
65. Amiri F, Garcia R. Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Am J Physiol 1999; 276: F691-F699.
66. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH. Tumor necrosis factor-alpha up-regulates angiotensin type 1 receptors on cardiac fibroblasts. Circ Res1999; 85: 272-279.
67. Kisley LR, Sakai RR, Fluharty SJ. Estrogen decreases hypothalamic angiotensin II ATI receptor binding and mRNA in the female rat. Brain Res 1999; 844: 34-42.
68. Krishnamurthi K Estrogen regulates angiotensin ATI receptor expression via cytosolic proteins that bind to the 5’ leader sequence of the receptor mRNA. Endocrinology 1999; 140: 5435-5438.
69. Nickenig G, Sachinidis A, Ko Y, Vetter H. Regulation of angiotensin ATI receptor gene expression during cell growth of vascular smooth muscle cells. Eur J Pharmacol 1996; 297: 307-312.
70. Sumners C, Watkins LL, Raizada MK. Adrenergic receptor-mediated down-regulation of angiotensin II receptors in neuronal cultures. Neurochem 1986; 47: 1117-1126.
71. Sasamura H Regulation of vascular type 1 angiotensin receptors by cytokines. Hypertension 1997; 30: 35-41.
72. Douglas JG. Estrogen effects on angiotensin receptors are modulated by pituitary in female rats. Am Physiol1987; 252 (Endocrinol Metab 15): E57-E62.
73. Tufro-McReddie A, Chevalier RL, Everett AD, Gomez RA. Decreased perfusion pressure modulates renin and ANG II type 1 receptor gene expression in the rat kidney. Am J Physiol 1993; 264 (Regulatory Integrative Comp Physiol 33): R696-R702.
74. Linas SL, Marzec-Calvert R, Ullian ME. K depletion alters angiotensin II receptor expression in vascular smooth muscle cells. Am] Physiol 1990; 258 (Cell Physiol 27): C849-C854.
75. Lu D, Sumners C, Raizada MK. Regulation of angiotensin II type 1 receptor mRNA in neuronal cultures of normotensive and spontaneously hypertensive rat brains by phorbol esters and forskolin. Neurochem1994; 62: 2079-2084.
76. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73.
77. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: Response to chronic angiotensin II or aldosterone administration. Lab Clin Med 1993; 122: 404-411.
78. Kitamura E Effect of angiotensin II infusion on glomerular II receptor in rats. Biochem Biophys Acta1986; 885: 309-316.
79. Nishimura H A novel in vivo mechanism for angiotensin type 1 receptor regulation. Kidney Int1997; 52: 345-355.
80. Ullian ME, Raymond JR, Willingham MC, Paul RV. Regulation of vascular angiotensin II receptors by EGF. Am J Physiol 1997; 273 (Cell Physiol 42): C1241- C1249.
81. Bruna RD, Ries S, Himmelstoss C, Kurtz A. Expression of cardiac angiotensin II AT, receptor genes in rat hearts is regulated by steroids but not by angiotensin II. Hypertension 1995; 13: 763-769.
82. Kalenga MK, de Gasparo M, Thomas K, de Hertogh R. Down-regulation of angiotensin AT! receptor by progesterone in human placenta. Clin Endocrinol Metab1996; 81: 998-1002.
83. Yang H, Lu D, Raizada MK. Lack of cross-talk between adrenergic and angiotensin type 1 receptors in neurons of spontaneously hypertensive rat brain. Hypertension 1996; 27:1277-1283.
84. Kakar SS Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun 1992; 183: 1090-1096.
85. Bird IM Potassium negatively regulates angiotensin II type 1 receptor expression in human adrenocortical H295R cells. Hypertension 1995; 25: 1129-1134.
86. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule.Clin Invest 1996; 97: 2745-2752.
87. Sechi LA Tissue-specific regulation of type 1 angiotensin II receptor mRNA levels in the rat. Hypertension 1996; 28: 403-408.
88. Nickenig G Up-regulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.
89. Nickenig G Hypercholesterolemia is associated with enhanced angiotensin ATl-receptor expression. Am J Physiol 1997; 272: H2701-H2707.
90. Warnholtz A Increased NADH-oxidase mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin angiotensin system. Circulation 1999; 99: 2027-2033.
91. Nickenig G Statin-sensitive dysregulated ATI receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
92. John S Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. Hypertens 1999; 17: 1933-1939.
93. Pitt B. The potenial use of angiotension-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol 1997; 79: 24-28.
94. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clini-cal evidence of heart failure. Lancet 1993; 342: 821- 828.
95. Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987; 316: 1429-1435.
96. Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-con verting-enzyme, ramipril, on cardiovascular events. N Engl J Med 2000; 342: 145-153.